The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 26, 2023
Filed:
Oct. 25, 2019
Ming-hsin LI, Taoyuan, TW;
Sheng-nan Lo, Taoyuan, TW;
Shih-wei Lo, Taoyuan, TW;
Shih-ying Lee, Taoyuan, TW;
Su-jung Chen, Taoyuan, TW;
Shih-min Wang, Taoyuan, TW;
Ming-wei Chen, Taoyuan, TW;
Wei-lin Lo, Taoyuan, TW;
Ming-Hsin Li, Taoyuan, TW;
Sheng-Nan Lo, Taoyuan, TW;
Shih-Wei Lo, Taoyuan, TW;
Shih-Ying Lee, Taoyuan, TW;
Su-Jung Chen, Taoyuan, TW;
Shih-Min Wang, Taoyuan, TW;
Ming-Wei Chen, Taoyuan, TW;
Wei-Lin Lo, Taoyuan, TW;
NATIONAL ATOMIC RESEARCH INSTITUTE, Taoyuan, TW;
Abstract
The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.